.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
UBS
Chubb
Cantor Fitzgerald
Julphar
Dow
Healthtrust
McKinsey
Colorcon
Teva

Generated: June 27, 2017

DrugPatentWatch Database Preview

Claims for Patent: 8,299,116

« Back to Dashboard

Claims for Patent: 8,299,116

Title:CCI-779 concentrate formulations
Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.
Inventor(s): Rubino; Joseph T (Towaco, NJ), Siskavich; Victoria (Lyon Mountain, NY), Harrison; Maureen M (Sugar Loaf, NY), Gandhi; Pooja (Highland Mills, NY)
Assignee: Wyeth LLC (Madison, NJ)
Application Number:13/206,641
Patent Claims: 1. A CCI-779 cosolvent concentrate for preparing a parenteral formulation upon admixture with a diluent, said concentrate comprising: about 1 mg/mL to about 25 mg/mL of CCI-779; about 15% w/v to about 60% w/v dehydrated ethanol; about 15% w/v to about 60% w/v propylene glycol; about 0.01% w/v to about 0.1% w/v of d,1-.alpha.-tocopherol; and about 0.001 to about 0.005% w/v of citric acid.

2. The CCI-779 cosolvent concentrate according to claim 1, wherein the citric acid is about 0.0025% w/v of the cosolvent concentrate.

3. The CCI-779 cosolvent concentrate according to claim 1, wherein the dehydrated ethanol is at least about 30% w/v of the cosolvent concentrate.

4. The CCI-779 cosolvent concentrate according to claim 1 , wherein the propylene glycol is about 35% w/v to about 50% w/v of the cosolvent concentrate.

5. The CCI-779 cosolvent concentrate according to claim 1, wherein the d,1-.alpha.-tocopherol is about 0.075% of the cosolvent concentrate.

6. The CCI-779 cosolvent concentrate according to claim 1, comprising about 25 mg/mL CCI-779; about 40% w/v of dehydrated ethanol; about 0.075% w/v of d,1-.alpha.-tocopherol; about 0.0025% w/v of citric acid; and about 35% w/v propylene glycol.

7. The CCI-779 cosolvent concentrate according to claim 1, which is diluted at a ratio of 1:1.5 to 1:2 concentrate to diluent to form the parenteral formulation.

8. A CCI-779 cosolvent concentrate for preparing a parenteral formulation upon admixture with a diluent, said concentrate consisting of about 1 to about 25 mg/mL of CCI-779, about 0.01 to 0.1% w/v of d,1-.alpha.-tocopherol, up to about 0.1% w/v of d,1-.alpha.-tocopherol, about 0.001 to about 0.005% w/v of citric acid, and about 15 to about 60% w/v of dehydrated ethanol and propylene glycol.

9. The CCI-779 cosolvent concentrate according to claim 8, comprising about 40% w/v dehydrated ethanol.

10. The CCI-779 cosolvent concentrate according to claim 8, comprising about 15% w/v to about 60% w/v propylene glycol.

11. The CCI-779 cosolvent concentrate according to claim 10, comprising about 50% w/v propylene glycol.

12. The CCI-779 cosolvent concentrate according to claim 8, comprising about 0.075% w/v of d,1-.alpha.-tocopherol.

13. The CCI-779 cosolvent concentrate according to claim 8, which is diluted at a ratio of 1:1.5 to 1:2 concentrate to diluent to form the parenteral formulation.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Federal Trade Commission
Baxter
Healthtrust
McKesson
Express Scripts
Julphar
Dow
Accenture
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot